Baricitinib
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Baricitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 31, 2018, and the first generic was approved Jul 22, 2024. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $35 million on Baricitinib across 9,553 claims for 1,609 beneficiaries.
Baricitinib is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $92.54 to $184.66 per EA — a 100% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$92.54 – $184.66
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Eli Lilly and Company manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Janus Kinase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing BARICITINIB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
OLUMIANT 4 MG TABLET | $184.6623 per EA | — |
OLUMIANT 2 MG TABLET | $92.5433 per EA | +0.01% |
Frequently Asked Questions
What is Baricitinib used to treat?
Baricitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.
When did Baricitinib become available as a generic?
FDA approved the first generic Baricitinib (ANDA) on Jul 22, 2024. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Baricitinib?
In 2024, Medicare Part D spent $35 million on Baricitinib across 9,553 claims for 1,609 beneficiaries.
How many Baricitinib products are on the market?
The Baricitinib drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Baricitinib?
NADAC reference prices for Baricitinib range from $92.5433 to $184.6623 per EA — a 100% difference between cheapest and most expensive.
Which manufacturers make Baricitinib?
1 manufacturer lists Baricitinib in NADAC. Ranked by number of NDCs, the largest are Eli Lilly and Company (2).
How has the price of Baricitinib changed recently?
Over the past 7 days, 1 Baricitinib NDC rose and 0 fell, with a market-wide average change of +0.0%.